Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925790 | 0.95 | TTK (0.47) | TTKCCNA2CDK2PTK2IGF1R | |
| Trifluoroacetic Acid SCHEMBL2935410 | 0.95 | CCNA2 (0.42) | TTKCCNA2CDK2PTK2IGF1R | |
| Trifluoroacetic Acid SCHEMBL2933549 | 0.94 | TTK (0.44) | TTKCCNA2CDK2PTK2IGF1R | |
| Trifluoroacetic Acid SCHEMBL2930408 | 0.93 | TTK (0.43) | TTKCCNA2CDK2PTK2IGF1R | |
| Trifluoroacetic Acid SCHEMBL2932629 | 0.92 | TTK (0.43) | TTKCCNA2CDK2PTK2IGF1R | |
| Trifluoroacetic Acid SCHEMBL2935933 | 0.90 | CCNA2 (0.42) | TTKCCNA2CDK2PTK2IGF1R | |
| Trifluoroacetic Acid SCHEMBL2934774 | 0.90 | TTK (0.42) | TTKCCNA2CDK2PTK2IGF1R | |
| SCHEMBL2929194 | 0.90 | TTK (0.45) | TTKCCNA2CDK2PTK2IGF1R | |
| SCHEMBL2927347 | 0.90 | TTK (0.47) | TTKCCNA2CDK2PTK2IGF1R | |
| Trifluoroacetic Acid SCHEMBL2934965 | 0.89 | PYGL (0.42) | TTKCCNA2CDK2PTK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | TTK 266/4885CCNA2 471/4885CDK2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.